Patient Characteristics, Associated Factors, and Clinical Outcomes of Prescribing Encorafenib and Binimetenib Versus Dabrafenib and Trametinib Among BRAF v600 Mutated Metastatic Melanoma Patients

CompletedOBSERVATIONAL

Enrollment

214

Participants

Timeline

Start Date

July 30, 2021

Primary Completion Date

March 28, 2022

Study Completion Date

March 28, 2022

Conditions

BRAF v600 Mutated Metastatic Melanoma

Trial Locations (1)

Novartis Pharmaceuticals, East Hanover